Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tocris Bioscience™ JB 300

Click to view available options
Quantity:
5 mg
Description
JB 300 is a potent and selective Aurora A Degrader (PROTAC™;; DC50 = 30 nM and Dmax = 78%). It comprises a cereblon E3-ligase ligand Thalidomide (Cat. No. 0652) joined by a PEG2 linker to the Aurora A inhibitor MK-5108. The compound depletes Aurora A in MV4-11 cell lines and exhibits no degradation of Aurora B at 10 μM. JB 300 shows dose-dependent cytotoxicity in AML cells .
PROTAC™; is a registered trademark of Arvinas Operations, Inc., and is used under license.
Specifications
Specifications
Chemical Name or Material | trans-4-(3-Chloro-2-fluorophenoxy)-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethoxy)ethyl)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxamide |
Quantity | 5 mg |
Target | Active Degraders |
Molecular Formula | C43H45ClFN7O10S |
Purity | 0.98 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction